Skip to main content
. Author manuscript; available in PMC: 2019 Mar 21.
Published in final edited form as: Int J Obes (Lond). 2018 Sep 21;43(6):1154–1163. doi: 10.1038/s41366-018-0207-x

Figure 2. Parts A-B: Dose effects of obesogenic medication on post-LSG weight loss outcomes.

Figure 2

(A) Patients who were exposed to obesogenic medications continuously for 12 months post-LSG (laparoscopic sleeve gastrectomy) had worse weight loss outcomes compared to those who were exposed for <12 months and those in the Control group. Error bars reflect SEM. (B) The more obesogenic medication a patient was prescribed, the worse the patient’s weight loss outcomes. Please note that the sum of patients on obesogenic meds at 12M (n=58) is less than that of individuals in the overall 12M obesogenic group (n=78) because the latter includes individuals who had obesogenic medications discontinued at some interim point during the 1-year post-operative period. Error bars reflect SEM.

* p < 0.05, ** p < 0.01, ***p < 0.001